GlycoNex Completes Patient Dosing for Phase 3 Trial of SPD8 Biosimilar for Osteoporosis GlycoNex has successfully completed the final patient dosing in its Phase 3 trial of SPD8, a denosumab biosimilar aimed at treating osteoporosis, with top-line results expected in 2026.

GlycoNex Completes Patient Dosing for Phase 3 Trial of SPD8 Biosimilar for Osteoporosis #Taiwan #New_Taipei_City #GlycoNex #SPD8 #Denosumab

GlycoNex Expands Global Reach with SPD8 Biosimilar License Agreement GlycoNex, Inc. announces a significant licensing agreement for their SPD8 biosimilar. This strategic move enhances their global expansion in innovative therapies in oncology.

GlycoNex Expands Global Reach with SPD8 Biosimilar License Agreement #Taiwan #New_Taipei_City #GlycoNex #SPD8 #Biosimilars

GlycoNex Begins Phase 3 Trial of SPD8 Biosimilar for Osteoporosis Treatment GlycoNex has announced the first patient dosed in a Phase 3 trial for its biosimilar, SPD8, aimed at treating osteoporosis. Results expected in 2026.

GlycoNex Begins Phase 3 Trial of SPD8 Biosimilar for Osteoporosis Treatment #Taiwan #New_Taipei_City #GlycoNex #SPD8 #Denosumab